Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Ratings for Inspire Medical Systems (NYSE:INSP) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 4 | 3 | 0 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 2 | 0 | 0 | 0 | 0 |
2M Ago | 0 | 1 | 0 | 0 | 0 |
3M Ago | 2 | 1 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $267.57, a high estimate of $285.00, and a low estimate of $250.00. This upward trend is evident, with the current average reflecting a 8.47% increase from the previous average price target of $246.67.
A comprehensive examination of how financial experts perceive Inspire Medical Systems is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Shagun Singh | RBC Capital | Announces | Outperform | $285.00 | - |
Anthony Petrone | Mizuho | Maintains | Buy | $250.00 | $250.00 |
Richard Newitter | Truist Securities | Maintains | Buy | $280.00 | - |
Kallum Titchmarsh | Morgan Stanley | Announces | Overweight | $250.00 | - |
Richard Newitter | Truist Securities | Raises | Buy | $280.00 | $265.00 |
Anthony Petrone | Mizuho | Raises | Buy | $250.00 | $225.00 |
Brett Fishbin | Keybanc | Announces | Overweight | $278.00 | - |
To gain a panoramic view of Inspire Medical Systems's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Inspire Medical Systems analyst ratings.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Inspire Medical Systems displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 39.6%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Inspire Medical Systems's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 7.67%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Inspire Medical Systems's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.64%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Inspire Medical Systems's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.24% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.04, Inspire Medical Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: INSP